Page 1 sur 1

[Pubmed] Therapeutic Strategies for Myasthenia Gravis

Posté : 17 mai 2023 12:00
par RSS-Bot

Brain Nerve. 2023 May;75(5):527-532. doi: 10.11477/mf.1416202372.

ABSTRACT

For years, the treatment of myasthenia gravis (MG) included high-dose oral steroids. This improved the mortality rate, but the adverse aspects of this treatment have become apparent. To overcome these statuses, an early fast-acting treatment strategy was advocated in the 2010s. Although this strategy improved the patients' quality of life, there are still many patients experiencing impaired activities of daily living. A certain number of so-called "refractory MG" patients also exist. Molecular-targeted drugs for MG have recently been developed. To date, three such drugs are available in Japan.

PMID:37194525 | DOI:10.11477/mf.1416202372


Source: https://pubmed.ncbi.nlm.nih.gov/3719452 ... t6+86293ac